SEngine Precision Medicine

SEngine Precision Medicine is a private, pre-revenue diagnostics company pioneering a functional precision oncology platform. Its core technology involves creating living, 3D tumor organoids from patient biopsies and screening them against a panel of oncology drugs to identify the most effective therapies. The company aims to address the high failure rate of standard genomic-based tests by providing a more direct, phenotypic readout of drug sensitivity. Its primary offering, the PARIS® test, is positioned to help oncologists make more informed, personalized treatment decisions for cancer patients.

Proprietary platform for generating and high-throughput drug screening of patient-derived organoids (PDOs), integrated with genomic and transcriptomic data analysis.

SEngine competes with large genomic profiling companies (e.g., Foundation Medicine, Guardant Health) and other functional diagnostic players using different ex vivo models (e.g., 2D cultures, micro-organospheres). Its primary differentiation is the use of 3D organoids, which may better mimic the tumor microenvironment. The competitive field is intensifying as the value of functional testing gains recognition.